NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
NEOGEN CORP
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026
$11.63−0.18 (-1.52%)
Close on Oct 19, 2026
- Market cap
- $2.54B
- P/E (TTM)
- –
- Dividend yield
- –
Neogen statistics
Financials through Aug 31, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Neogen | Industry median |
|---|---|---|
| Market Cap | $2.54B | $197.05M |
| Enterprise Value | $3.92B | $106.56M |
| PS Ratio | 2.87 | 3.93 |
| PB Ratio | 1.22 | 2.14 |
| P/FCF Ratio | 50.92 | 18.25 |
| P/OCF Ratio | 29.73 | 13.78 |
Enterprise value
| Measure | Neogen | Industry median |
|---|---|---|
| EV / Sales | 4.43 | 2.69 |
| EV / EBITDA | 35.97 | 14.86 |
| EV / FCF | 78.68 | 21.02 |
Income (trailing twelve months)
| Measure | Neogen | Industry median |
|---|---|---|
| Revenue | $883.99M | $57.94M |
| Gross Profit | $418.98M | $90.47M |
| Operating Income | -$7.38M | -$21.44M |
| Pretax Income | -$67.66M | -$14.45M |
| Net Income | -$56.12M | -$22.46M |
| EBITDA | $108.92M | -$16.91M |
| EPS (Diluted) | -$0.25 | -$0.83 |
Margins
| Measure | Neogen | Industry median |
|---|---|---|
| Gross Margin | 47.4% | 52.3% |
| Operating Margin | -0.83% | -44.5% |
| Pretax Margin | -7.65% | -13.0% |
| Profit Margin | -6.35% | -39.2% |
| EBITDA Margin | 12.3% | -31.3% |
| FCF Margin | 5.63% | -8.85% |
Returns
| Measure | Neogen | Industry median |
|---|---|---|
| Return on Equity (ROE) | -2.67% | -53.1% |
| Return on Assets (ROA) | -1.68% | -41.0% |
| Return on Invested Capital (ROIC) | -0.17% | -32.0% |
| Return on Capital Employed (ROCE) | -0.23% | -37.8% |
Growth
| Measure | Neogen | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -0.33% | 6.01% |
| Revenue Growth (3Y CAGR) | 1.91% | 2.25% |
| Revenue Growth (5Y CAGR) | 13.2% | 6.42% |
Balance sheet
| Measure | Neogen | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $172.00M | $62.42M |
| Total Debt | $1.55B | $120.13M |
| Net Cash (Debt) | -$1.38B | $15.68M |
| Net Cash Per Share | -$6.34 | $0.65 |
| Equity (Book Value) | $2.09B | $48.79M |
| Book Value Per Share | $9.57 | $1.36 |
| Tangible Book Value | -$257.00M | $23.06M |
| Working Capital | $433.00M | $75.77M |
Financial position
| Measure | Neogen | Industry median |
|---|---|---|
| Current Ratio | 3.90 | 3.30 |
| Quick Ratio | 2.06 | 2.39 |
| Debt / Equity | 0.74 | 0.51 |
| Debt / EBITDA | 14.27 | 3.35 |
| Debt / FCF | 31.21 | 5.05 |
| Net Debt / EBITDA | 12.69 | 2.22 |
Cash flow (trailing twelve months)
| Measure | Neogen | Industry median |
|---|---|---|
| Operating Cash Flow | $85.30M | -$12.35M |
| Capital Expenditures | -$35.50M | -$1.06M |
| Free Cash Flow | $49.80M | -$20.28M |
| FCF Per Share | $0.23 | -$0.41 |
Efficiency
| Measure | Neogen | Industry median |
|---|---|---|
| Asset Turnover | 0.26 | 0.38 |
| Inventory Turnover | 2.74 | 2.67 |
| Revenue Per Employee | $335.35K | $398.96K |
| Profits Per Employee | -$21.29K | -$732.08K |
| Employee Count | 2,636 | 73 |
Dividends and yields
| Measure | Neogen | Industry median |
|---|---|---|
| Earnings Yield | -2.21% | -21.2% |
| FCF Yield | 1.96% | -7.64% |
Shares
| Measure | Neogen | Industry median |
|---|---|---|
| Shares Outstanding | 218,056,000 | 59,128,900 |
| Shares Change (YoY) | 0.13% | 11.1% |
| Shares Change (QoQ) | 0.28% | 0.54% |
| Float | 216,867,000 | 48,744,500 |
| Shares Held by Insiders | 0.55% | 11.8% |
| Shares Held by Institutions | 108.9% | 59.4% |
Taxes
| Measure | Neogen | Industry median |
|---|---|---|
| Income Tax | -$11.54M | $91.50K |
Scores
| Measure | Neogen | Industry median |
|---|---|---|
| Altman Z-Score | 1.43 | 0.10 |
| Piotroski F-Score | 6 | 4 |
| Beneish M-Score | -2.64 | -2.62 |
Calculated by StockData from Neogen's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.